Clinical trialNCT03102606CompletedPhase 3Interventional

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3

SponsorBeyondSpring Pharmaceuticals Inc.Enrollment105Chemotherapy-induced Neutropenia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

To assess Duration of Severe Neutropenia (DSN) in treatment Cycle 1 in patients with advanced or metastatic breast cancer, who have failed \>/= 1 but \< 5 prior lines of chemotherapy; locally advanced or metastatic non small cell lung cancer (NSCLC) after platinum therapy failure; or hormone refractory (androgen independent) metastatic prostate cancer treated with docetaxel (75 mg/m2) + plinabulin (40 mg) versus docetaxel (75 mg/m2) + pegfilgrastim (6 mg). Neutrophils count will be assessed at baseline; Pre dose during Cycle 1, Day 1, 2, 6, 7, 8, 9, 10, 15. \*Study is officially closed on 08 Feb 2021\*

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Douglas W. Blayney, MD
Stanford University School of Medicine - Cancer Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China

Heilongjiang Cancer Hospital
Harbin, Heilongjiang, China
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China
Linyi Cancer Hospital
Linyi, China
Liaoning Cancer Hospital & Institute
Shenyang, China
Henan Cancer Hospital
Zhengzhou, China

Russia

State Budgetary Healthcare Institution of Stavropol Territory "pyatigorsk Interregional Oncology Dispensary"
Pyatigorsk, Russia
Sbi of Healthcare "oncology Dispensary #2" Ministry of Healthcare of Krasnodar Region
Sochi, Russia
Volgograd Regional Clinical Oncology Dispensary
Volgograd, Russia

Ukraine

Dnipropetrovsk City Multifunctional Hospital
Dnipro, Ukraine
Prykarpatskiy Regional Oncological Center
Ivano-Frankivsk, Ukraine
Communal Institution of Kherson Regional Council "kherson Regional Oncological Dispensary"
Kherson, Ukraine
Kryvyi Rih Oncology Dispensary
Kryvyi Rih, Ukraine
Lviv State Oncological Regional Treatment and Preventive Center
Lviv, Ukraine
Municipal Institution "sumy Regional Clinical Oncology Dispensary"
Sumy, Ukraine

United States

Stanford University School of Medicine - Cancer Institute
Stanford, California, United States
Hematology/oncology of the North Shore
Skokie, Illinois, United States
Norton Cancer Institute
Louisville, Kentucky, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Pegfilgrastim →Plinabulin

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 29 May 2018
Primary completion: 12 Dec 2018
Completion: 8 Feb 2021
Last update posted: 29 Aug 2024
Registered enrollment: 105
Registry id: NCT03102606

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.